For the quarter ending 2026-03-31, ALT has $335,630K in assets. $51,643K in debts. $97,601K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 97,601 | 61,236 | 183,105 | |
| Restricted cash | 42 | 42 | 42 | |
| Total cash, cash equivalents and restricted cash | 97,643 | 61,278 | 183,147 | |
| Short-term investments | 233,939 | 149,540 | - | |
| Accounts and other receivables | 1,665 | 845 | 321 | |
| Income tax and r&d incentive receivables | - | 547 | 557 | |
| Prepaid expenses and other current assets | 1,429 | 4,405 | 4,397 | |
| Total current assets | 334,676 | 216,615 | 188,422 | |
| Property and equipment, net | 208 | 337 | 364 | |
| Other assets | 746 | 1,495 | 1,564 | |
| Total assets | 335,630 | 218,447 | 190,350 | |
| Accounts payable | 1,530 | 4,804 | 851 | |
| Accrued expenses and other current liabilities | 9,793 | 7,802 | 8,369 | |
| Total current liabilities | 11,323 | 12,606 | 9,220 | |
| Term loan, noncurrent | 34,505 | 14,445 | 14,332 | |
| Other noncurrent liabilities | 5,815 | 5,795 | 5,431 | |
| Total liabilities | 51,643 | 32,846 | 28,983 | |
| Common stock, 0.0001 par value 200,000,000 shares authorized 130,221,154 and 110,882,735 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 13 | 10 | 9 | |
| Additional paid-in capital | 961,244 | 812,732 | 769,508 | |
| Accumulated deficit | -672,046 | -622,125 | -603,111 | |
| Accumulated other comprehensive loss, net | -5,224 | -5,016 | -5,039 | |
| Total stockholders' equity | 283,987 | 185,601 | 161,367 | |
| Total liabilities and stockholders' equity | 335,630 | 218,447 | 190,350 | |
Altimmune, Inc. (ALT)
Altimmune, Inc. (ALT)